By John Sayre, Senior Vice President of Development Operations at Gilead
When I was in college, I learned about the Spanish Flu in a class on the history of medicine. I found the pandemic so fascinating that I reached out to my grandmother Cordelia to ask her about it. She was about 80 by then but still remembered it vividly. She described driving through a neighborhood in Akron, Ohio at the age of 15 and seeing people throwing furniture out of an attic window. Everyone in the house had died, and they were burning everything inside to kill the germs.
Gilead views environmental stewardship as critical to help the company achieve its mission and last year announced a goal to reduce greenhouse gas emissions at least 25% by 2025, against a 2016 baseline.
As the number of confirmed COVID-19 cases increased in Asia and began to spread to other regions around the world, a team of employees at Gilead’s manufacturing site in La Verne, California met in the early morning of Monday, Feb. 3.
The topic of the meeting: How quickly could the site begin to formulate, fill, package and ship Gilead’s investigational COVID-19 treatment, remdesivir?
Nearly a year ago, President Trump announced an aspirational goal in his State of the Union address: to reduce the number of new HIV infections in the U.S. by 75% within five years, and by at least 90% within 10 years. This goal is certainly ambitious – but it is not unreachable.
By Douglas Brooks, Executive Director, Community Engagement at Gilead
Every now and then, I allow myself to revisit a time when I feared hearing the phone ring. That such an ordinary occurrence could induce deep emotion reflected the environment in which many of us resided. Knowing that the call could easily be the news of another friend having died or having been rushed to the hospital sometimes froze me in place.
By Diana Brainard, MD, Senior Vice President for HIV and Emerging Viruses at Gilead
When I was a medical student in the mid-1990s, the scope and impact of the HIV/AIDS epidemic was devastating and there was little hope for long-term survival. During rotations at Charity Hospital in New Orleans, I observed people living with HIV demonstrate courage, as well as numerous healthcare professionals providing compassionate care.